CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.22 -2.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.22

Максимум

1.3

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+807.14% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-162M 464M
Предишно отваряне	3.62
Предишно затваряне	1.22

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.06.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9.06.2026 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9.06.2026 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9.06.2026 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9.06.2026 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9.06.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9.06.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Additional Investment Makes It Largest Shareholder in Element

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9.06.2026 г., 20:51 ч. UTC

Печалби

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.06.2026 г., 20:09 ч. UTC

Пазарно говорене

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9.06.2026 г., 19:36 ч. UTC

Пазарно говорене

Cattle Climbs as Crude Oil Falls -- Market Talk

9.06.2026 г., 19:32 ч. UTC

Пазарно говорене

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9.06.2026 г., 19:25 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9.06.2026 г., 19:00 ч. UTC

Пазарно говорене

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9.06.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9.06.2026 г., 18:47 ч. UTC

Пазарно говорене

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9.06.2026 г., 18:37 ч. UTC

Пазарно говорене

Canada's Cooling Trade With the U.S. -- Market Talk

9.06.2026 г., 18:27 ч. UTC

Пазарно говорене

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9.06.2026 г., 17:35 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9.06.2026 г., 17:30 ч. UTC

Пазарно говорене

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9.06.2026 г., 16:34 ч. UTC

Пазарно говорене

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.06.2026 г., 15:28 ч. UTC

Пазарно говорене

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9.06.2026 г., 15:25 ч. UTC

Пазарно говорене

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

807.14% нагоре

12-месечна прогноза

Среден 11.43 USD 807.14%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.